Search the Newsreel

Somi Conveyor Beltings net profit falls 50% in Q1FY27 on revenue slump

AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242

Morgan Stanley has increased its target price for Axsome Therapeutics, Inc. (AXSM) to $251 from $242. This update reflects an analyst's revised valuation for the company. The article, sourced from Reuters, provides this key financial adjustment.

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00

Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Axsome Therapeutics has delivered a very large 5 year return while the current valuation …

Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM)

Axsome Therapeutics, Inc. reported increased revenue in Q2 2026 but also widened net losses, driven by expanding its CNS portfolio and commercialization efforts. While revenue growth is strong, the growing net loss and cash burn raise concerns for investors regarding the company's ability to …

What's Going On With Blossom Gold Inc. Stock Monday?

Axsome Therapeutics (NASDAQ: AXSM) grows Q2 2026 revenue but remains unprofitable

Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA

Earnings Call Insights: Axsome Therapeutics (AXSM) Q2 2026 MANAGEMENT VIEW * "The second quarter was highly productive for Axsome as we grew our commercial business robustly and made important regulatory and clinical progress across our innovative neuroscience pipeline," said "Founder, Chairman, CEO & President …

Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss

Axsome Therapeutics (NASDAQ:AXSM) shares rose 2.09% in pre-market trading despite missing Q2 earnings and revenue expectations, as investors focused on robust underlying product growth. The company reported a wider loss of $0.99 per share and revenue of $218.4 million, but sales surged 46% year-over-year, …

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

Axsome Therapeutics Q2 Earnings Call Highlights

Why Blossom Gold Inc. stock surged yesterday

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics (NASDAQ:AXSM) Issues Quarterly Earnings Results

Axsome Therapeutics Inc earnings missed by $0.14, revenue fell short of estimates

Axsome Therapeutics Inc (NASDAQ: AXSM) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.99 against an estimated $-0.85, and revenue of $218.37M fell short of the $221.92M consensus. Despite the recent miss, the stock …

Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q2 Revenue $218.4M, vs. FactSet Est of $221.1M

Axsome Therapeutics, Inc. (AXSM) reported its Q2 revenue at $218.4 million, falling short of the FactSet estimate of $221.1 million. The company's stock was trading at $219.19 USD with a 3.03% change on August 10, 2026. This earnings flash was published at 07:21 am …

Axsome Reports 126% More AUVELITY Starts Among 65+ Patients in 8 Weeks

Axsome Therapeutics announced strong financial results for Q2 2026, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by significant growth in sales of AUVELITY, SUNOSI, and SYMBRAVO. The company reported a net loss of $51.3 million but indicated that current …

Axsome Therapeutics (NASDAQ: AXSM) Q2 revenue jumps 46% as CNS pipeline advances

Axsome Therapeutics reported strong Q2 2026 revenue growth, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by AUVELITY, SUNOSI, and SYMBRAVO sales. Despite this growth, the company posted a net loss of $51.3 million due to higher SG&A expenses from …

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics reported strong second-quarter 2026 financial results, with total net product revenue reaching $218.4 million, a 46% year-over-year increase, driven by significant growth in AUVELITY sales. The company also provided a business update highlighting the launch of AUVELITY for agitation associated with Alzheimer’s …

Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build

Axsome Therapeutics (AXSM) is considered 25% undervalued with a fair value of $282.51, despite a recent 9% stock decline. The valuation is driven by its expanding CNS portfolio, late-stage clinical programs, and projected rapid revenue growth and margin improvements. However, the company faces risks …

Winsome Textile net profit rises 26% in Q1FY27 on lower finance costs

How Axsome Therapeutics Inc. (AXSM) Affects Rotational Strategy Timing

Axsome Therapeutics Inc. (AXSM) is analyzed through institutional trading strategies by Stock Traders Daily. The report identifies weak near and mid-term sentiment but a strong long-term outlook for AXSM, highlighting specific entry, target, and stop-loss points for position, momentum, and risk-hedging strategies. AI-generated signals …

Ausom Enterprise Ltd is Rated Hold by MarketsMOJO

AXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More

AXSOME THERAPEUTICS ($AXSM) is set to release its Q2 2026 earnings on August 10th, with analysts projecting revenues of $225.45 million and an EPS of -$0.86. The article details recent insider trading activity, showing 16 sales and zero purchases over the last six months …

Axsome Therapeutics, Inc. $AXSM Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in Axsome Therapeutics by 3.2% in the first quarter, selling 19,942 shares and retaining 598,091 shares worth $101.1 million. Despite mixed analyst ratings, the company holds a "Moderate Buy" consensus with a $265.55 price target. Over …

Somnigroup International (SGI) Stock Faces Premium Payout Question After EPS Surge

Axsome therapeutics CEO Herriot Tabuteau sells $10.5m in shares

Axsome Therapeutics CEO Herriot Tabuteau sold approximately $10.5 million worth of common stock on August 5 and 6, 2026, following the exercise of stock options that were nearing their expiration date. These transactions were executed under a pre-approved 10b5-1 trading plan. Despite the sales, …

SOMNIGROUP INTERNATIONAL INC. 2026: Revenue $1.82B, EPS $0.52— 10-Q Summary

SOMNIGROUP INTERNATIONAL INC. (SGI) reported its 2026 quarterly results, showing a slight decrease in revenue to $1.82 billion, down 3% year-over-year. Despite the revenue dip, net income increased by 11.2% to $110.6 million, and diluted EPS rose by 10.6% to $0.52. The company highlighted …

Blossom Gold Sheds 3.5% as Nevada Explorer Digests a Big Run

SOM Distilleries & Breweries Q1 Results: Earnings Call Scheduled for August 13

Somnigroup International (NYSE: SGI) lifts profit, details Mattress Firm synergies and $2.5B deal

Somerset Minerals seeks shareholder approval on major share and option issuances

Somerset Minerals Calls September General Meeting, Moves to Digital Notices

Axsome Therapeutics (AXSM) Stock Looks Near Fair Value Despite Premium Sales Pricing

Axsome Therapeutics (AXSM) stock appears to be priced near its fair value, despite its premium sales pricing, following a significant 5-year gain and a recent pullback. The company's P/S ratio of 15.3x is higher than industry averages but aligns closely with its estimated fair …

AXSM (AXSM) holder files to sell 4,660 shares via cashless option exercise

A holder of Axsome Therapeutics (AXSM) has filed a Form 144 to sell 4,660 common shares through a cashless option exercise, valued at approximately $979,205.80. These shares, acquired in 2017 as compensation via stock options, are intended for sale on or after August 6, …

Somnigroup International Inc (SGI) (Q2 2026) Earnings Call Highlights: Record EPS and Cash Flow ...

This article first appeared on GuruFocus. Net Sales: $1.8 billion in the second quarter of 2026. Adjusted EPS: $0.58, a 9% increase from the prior year. Adjusted EBITDA: $297 million in the second quarter. Mattress Firm Net Sales: Approximately $922 million in the second …